Patent ID: 8623829
Filing Date: 2014-01-07
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method of treating a cancer expressing URLC10 and HLA-A2 in a subject, said method comprising administering to said subject a composition comprising a peptide selected from the group consisting of the following (i) and (ii), or a polynucleotide encoding said peptide: (i) an isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises the amino acid sequence of SEQ ID NO: 288; and (ii) an isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence of SEQ ID NO: 288 in which 1 or 2 amino acids are substituted.